Literature DB >> 2124271

The limitations of IgM assays in the serological diagnosis of Mycoplasma pneumoniae infections.

M Sillis1.   

Abstract

The most useful and reliable serological investigations for the diagnosis of current Mycoplasma pneumoniae infection, including reinfection, were investigated. Paired sera and respiratory specimens from 115 patients with lower respiratory tract symptoms were examined for evidence of current M. pneumoniae infection by serological response, as measured by complement-fixation and indirect immunofluorescence tests for specific IgM, IgA and IgG, and also by culture of M. pneumoniae from respiratory material. Specific IgM was not always detectable in cases where other criteria indicated current or recent infection. On the basis of the present results, it is postulated that primary infection and reinfection may be differentiated by the presence or absence of specific IgM in the presence of elevated specific IgA levels and, therefore, that estimation of both IgM and IgA is necessary for the maximal detection of current M. pneumoniae infection, including reinfections. Specific IgG levels remained elevated for many weeks and were not useful diagnostically.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2124271     DOI: 10.1099/00222615-33-4-253

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  30 in total

1.  Indirect enzyme-linked immunosorbent assay for detection of immunoglobulin G reactive with a recombinant protein expressed from the gene encoding the 116-kilodalton protein of Mycoplasma pneumoniae.

Authors:  M F Duffy; K G Whithear; A H Noormohammadi; P F Markham; M Catton; J Leydon; G F Browning
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

2.  Rapid-cycle PCR for detection and typing of Mycoplasma pneumoniae in clinical specimens.

Authors:  F Kong; S Gordon; G L Gilbert
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

3.  Rapid, sensitive detection of Mycoplasma pneumoniae in simulated clinical specimens by DNA amplification.

Authors:  G E Buck; L C O'Hara; J T Summersgill
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

4.  Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the "gold standard".

Authors:  Matthias F C Beersma; Kristien Dirven; Alje P van Dam; Kate E Templeton; Eric C J Claas; Herman Goossens
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

5.  Mycoplasma pneumoniae Pneumonia with Worsening Pleural Effusion Despite Treatment with Appropriate Antimicrobials: Case report.

Authors:  Kowthar S Hassan; Ghalib Al-Khadouri
Journal:  Sultan Qaboos Univ Med J       Date:  2018-09-09

6.  Enzyme immunoassay for detection of immunoglobulin M (IgM) and IgG antibodies to Mycoplasma pneumoniae.

Authors:  S A Uldum; J S Jensen; J Søndergård-Andersen; K Lind
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948

Review 7.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  Comparison of two rapid commercial tests with complement fixation for serologic diagnosis of Mycoplasma pneumoniae infections.

Authors:  W L Thacker; D F Talkington
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

9.  Community outbreak of acute respiratory infection by Mycoplasma pneumoniae.

Authors:  A Domínguez; S Minguell; J Torres; A Serrano; J Vidal; L Salleras
Journal:  Eur J Epidemiol       Date:  1996-04       Impact factor: 8.082

10.  Analysis of eight commercial enzyme immunoassay tests for detection of antibodies to Mycoplasma pneumoniae in human serum.

Authors:  Deborah F Talkington; Susan Shott; Michael T Fallon; Stephanie B Schwartz; W Lanier Thacker
Journal:  Clin Diagn Lab Immunol       Date:  2004-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.